1.	Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: ADO-MM-PAL8, NCT00226473
2.	Characterization of the Melanoma-Specific Immune Response Phase: Phase IV Type: Biomarker/Laboratory analysis Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 200513097-1, NCT00368615
3.	HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12PLK01, NCT01683188
4.	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230B2412, NCT01794793
5.	Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Trial Photoderm Graz 2010-1, NCT01088737
6.	Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CASVAC0401, NCT01729663
7.	A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11718, UVACC-ONYX-11718, UVACC-HIC-11860, EUDRACT-2005-0000941-12, BAYER-UVACC-ONYX-11718, NCT00111007
8.	Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: MM-ADJ-5, NCT00226408
9.	Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 05 DIVE 03, NCT00224744
10.	18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology Phase: Phase III Type: Diagnostic Status: Active Age: 19 to 90 Sponsor: Other Protocol IDs: R05-0076, NCT00207298
11.	Multicenter Selective Lymphadenectomy Trial II (MSLT-II) Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: MSLT-II, NIH P01 CA029605, NCT00297895
12.	Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 101.321-13/07, EudraCT Nr. 2008-001686-28, NCT00779714
13.	Study Comparing Isolated Pelvic Perfusion With TNF-a 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 76 Sponsor: Other Protocol IDs: PIP2, CSET 1443, NCT00949039
14.	Neurotropic Melanoma of the Head and Neck Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TROG 08.09, 2009/039, NCT00975520
15.	Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-154, NCT01223248
16.	MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: S480/209, 2009-012049-46, NCT01264874
17.	Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02649, E1609, CDR0000692568, U10CA021115, ECOG-E1609, NCT01274338
18.	A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AB08026, NCT01280565
19.	A Study of RO5185426 in Patients With Metastatic Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO25515, NCT01307397
20.	Melanoma Margins Excision Trial Phase: Phase III Type: Health services research, Supportive care, Treatment Status: Approved-not yet active Age: 18 to 85 Sponsor: Other Protocol IDs: 2011PLAS03, NCT01457157
21.	Adjuvant PEG Intron in Ulcerated Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: EORTC-18081, 2009-010273-20, NCT01502696
22.	Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ANZMTG 01-07, ACTRN12607000512426, NCT01503827
23.	Managing Cancer and Living Meaningfully (CALM): A Study to Evaluate the Effectiveness of a Psychological Intervention for Cancer Patients Phase: Phase III Type: Educational/Counseling/Training, Supportive care Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UHN REB 09-0855-C, CIHR, NCT01506492
24.	Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA184-169, 2011-004029-28, NCT01515189
25.	Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: 103A-301, NCT01546571